TW202346345A - 面肩胛肱肌失養症（ｆｓｈｄ）之新治療 - Google Patents

面肩胛肱肌失養症（ｆｓｈｄ）之新治療 Download PDF

Info

Publication number
TW202346345A
TW202346345A TW112112383A TW112112383A TW202346345A TW 202346345 A TW202346345 A TW 202346345A TW 112112383 A TW112112383 A TW 112112383A TW 112112383 A TW112112383 A TW 112112383A TW 202346345 A TW202346345 A TW 202346345A
Authority
TW
Taiwan
Prior art keywords
myostatin
antibody
seq
treatment
myostatin antibody
Prior art date
Application number
TW112112383A
Other languages
English (en)
Chinese (zh)
Inventor
艾萊妮 蓋奇
譚美 麥可艾佛
斯蓋爾蔻 蕾娜塔 西西里安妮
凱薩琳 蕾 偉格納
慧姸 楊
Original Assignee
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商赫孚孟拉羅股份公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW202346345A publication Critical patent/TW202346345A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW112112383A 2022-04-01 2023-03-30 面肩胛肱肌失養症（ｆｓｈｄ）之新治療 TW202346345A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22166261 2022-04-01
EP22166261.2 2022-04-01

Publications (1)

Publication Number Publication Date
TW202346345A true TW202346345A (zh) 2023-12-01

Family

ID=81328333

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112112383A TW202346345A (zh) 2022-04-01 2023-03-30 面肩胛肱肌失養症（ｆｓｈｄ）之新治療

Country Status (11)

Country Link
US (1) US20250171526A1 (enExample)
EP (1) EP4504779A1 (enExample)
JP (1) JP2025511167A (enExample)
KR (1) KR20240165959A (enExample)
CN (1) CN119053619A (enExample)
AU (1) AU2023246859A1 (enExample)
CA (1) CA3255735A1 (enExample)
IL (1) IL315473A (enExample)
MX (1) MX2024011922A (enExample)
TW (1) TW202346345A (enExample)
WO (1) WO2023187022A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026147753A1 (en) * 2024-12-30 2026-07-09 Scholar Rock, Inc. Therapies for muscular dystrophies
US20260199503A1 (en) 2025-01-10 2026-07-16 Regeneron Pharmaceuticals, Inc. Glp1r agonist-tethered gdf8 antibody conjugates and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201891420A1 (ru) 2015-12-18 2019-02-28 Чугаи Сейяку Кабусики Кайся Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения

Also Published As

Publication number Publication date
MX2024011922A (es) 2024-11-08
EP4504779A1 (en) 2025-02-12
CN119053619A (zh) 2024-11-29
KR20240165959A (ko) 2024-11-25
AU2023246859A1 (en) 2024-09-05
IL315473A (en) 2024-11-01
AU2023246859A9 (en) 2024-09-12
WO2023187022A1 (en) 2023-10-05
US20250171526A1 (en) 2025-05-29
JP2025511167A (ja) 2025-04-15
CA3255735A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
AU2020210134B2 (en) Use of myostatin inhibitors and combination therapies
JP7426369B2 (ja) 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途
US20230365669A1 (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
US20250171526A1 (en) Treatment for Facioscapulohumeral Muscular Dystrophy (FSHD)
JP2010524846A (ja) 抗スクレロスチン抗体
US20240358704A1 (en) Combined administration
CN108367074A (zh) 使用白介素-17（il-17）拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
WO2019173352A1 (en) Methods for the treatment of thyroid eye disease
US20210253687A1 (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
KR20220054608A (ko) ActRII 수용체 길항제를 포함하는 간 질환 또는 장애 치료제
TW202434633A (zh) 治療甲狀腺眼疾之方法
TW202214297A (zh) 用於治療疼痛之結合TGF-α及表皮調節素(EPIREGULIN)之抗體
AU2018361975A1 (en) Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
KR20190090820A (ko) 오피오이드 중독 방지를 위한 약학 조성물
HK40112393A (en) New treatment for facioscapulohumeral muscular dystrophy (fshd)
HK40103690A (en) Novel combined administration
WO2026082814A1 (en) Anti- igfbp7 antibodies and uses thereof